Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Could high concentration homocystein in blood serum provide to recurrent miscarriages?
1
Klinika Położnictwa i Ginekologii Katedry Położnictwa i Ginekologii Śląskiego Uniwersytetu Medycznego w Katowicach; Katedra i Zakłady Anestezjologii Intensywnej Terapii Medycyny Ratunkowej Śląskiego Uniwersytetu Medycznego w Katowicach
Corresponding author
Jacek Magnucki
Klinika Położnictwa i Ginekologii Katedry Położnictwa i Ginekologii SUM w Katowicach, 40-752 Katowice, ul. Medyków 14, tel.: +48 601 38 18 88, fax: (+48 32 252 53 02)
Klinika Położnictwa i Ginekologii Katedry Położnictwa i Ginekologii SUM w Katowicach, 40-752 Katowice, ul. Medyków 14, tel.: +48 601 38 18 88, fax: (+48 32 252 53 02)
Ann. Acad. Med. Siles. 2009;63:84-92
KEYWORDS
ABSTRACT
A high level of homocysteine can be one of potential causative factors of habitual miscarriages. As it can be viewed from the press review, despite numerous examinations of different negative effects of the high level of homocysteine in the human organism, up till now no specific critical concentration values of this amino acid in blood serum have been determined, above which pathological vascular changes can be caused and in consequence pregnancy loss. Very significant for pregnancy growth is also the appropriate concentration of folic acid and vitamin B12 in the pregnant woman organism. Among the results of hyperhomocysteine there are changes in endothelium of the blood vessels, with accompanying irregularities in blood coagulation system.
REFERENCES (70)
1.
Sztenc S.: Hiperhomocysteinemia a powikłania ciąży. Ginekol. Pol. 2004; 75(4): 317-325.
2.
Domagała B., Sanak M., Czachór R., et al.: Hiperhomocysteinemia i jej związek z miażdżycą tętnic. Pol. Arch. Med. Wewn. 1997; 98(8): 153-162.
3.
Finkelstein J.D.: Pathways and regulation of homocysteine in mammals. Semin. Thromb. Hemost. 2000; 26(3): 219-225.
4.
Magott M.: Homocysteina nielipidowym czynnikiem patogenezy miażdżycy. Post. Hig. Med. Dośw. 1998; 52(3): 259-266.
5.
Cichocka A., Cybulska B.: Homocysteina - mniej poznany czynnik ryzyka chorób sercowo- naczyniowych. Med. Metab. 1999; 3(2): 42-52.
6.
Cotter A.M., Molloy A.M., Scott J.M., et al.: Elevated plasma homocysteine in early pregnancy: a risk factor for the development of nonsevere preeclampsia. Am. J. Obstet. Gynecol. 2003; 189(2): 391-396.
7.
Eskes T.K.: Clotting disorders and placental abruption: homocysteine - a new risk factor. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001; 95(2): 206-212.
8.
Gris J.C., Perneger T.V., Quere I., et al.: Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched casecontrol study. Blood 2003; 102(10): 3504- 3513.
9.
Ray J.G., Laskin C.A.: Folic acid and homocysteine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 1999; 20(7): 519-529.
10.
Wenstrom K.D., Johanning G.L., Johnston K.E., et al.: Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am. J. Obstet. Gynecol. 2001; 184(5): 806-817.
11.
Chambers J.C., McGregor A., Jean-Marie J., et al.: Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998; 351(9095): 36-37.
12.
Benirschke K, Kaufmann P.: Lupus erythematosus and lupus anticoagulant. W: Pathology of the human placenta. 2nd ed. New York: Springer Verlag, 1990. s. 530- 551.
13.
Fattal-Valevski A., Bassan H., Korman S.H., et al.: Methylenetetrahydrofolate reductase deficiency: importance of early diagnosis. J. Child Neurol. 2000; 15(8): 539- 543.
14.
Jacobsen D.W.: Homocysteine and vitamins in cardiovascular disease. Clin. Chem. 1998; 44(8 Pt 2): 1833-1843.
15.
Łopaciuk S.: Wrodzona trombofilia. W: Zakrzepy i zatory. Red. S. Łopaciuk. Wyd. 2 zm. i unowocześn. Warszawa: Wydaw. Lekarskie PZWL, 2002. s. 65-88.
16.
Piechota W.: Homocysteina - nowy czynnik ryzyka chorób układu krążenia. Warszawa: Abbot Laboratories Poland sp. z o.o., 1998.
17.
McQuillan B.M., Beilby J.P., Nidorf M., et al.: Hyperhomocysteinemia but not the C667T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. Circulation 1999; 99(18): 2383-2388.
18.
Rozen R.: Genetic modulation of homocysteinemia. Semin. Thromb. Hemost. 2000; 26(3): 255-261.
20.
Thambyrajah J., Landray M.J., McGlynn F.J., et al.: Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 2000; 102(8): 871-875.
21.
Schneede J., Refsum H., Ueland P.M.: Biological and enviromental determinants of plasma homocysteine. Semin. Thromb. Hemost. 2000; 26(3): 263-279.
22.
van Guldener C., Robinson K.: Homocysteine and renal disease. Semin. Thromb. Hemost. 2000; 26(3): 313-324.
23.
Appel L.J., Miller E.R., Jee S.H., et al.: Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. Circulation 2000; 102(8): 852-857.
24.
Ueland M., Refsum H.: Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J. Lab. Clin. Med. 1989; 114(5): 473-501.
25.
Henderson I.C.: Adjuvant therapy for breast cancer. N. Engl. J. Med. 1988; 318(7): 443-444.
26.
Ubbink J.B.: Assay methods for the measurement of total homocysteine in plasma. Semin. Thromb. Hemost. 2000; 26(3): 233- 241.
27.
Pronicka E.: Choroby metaboliczne. W: Pediatria. Red. K. Kubicka, W. Kawalec. Warszawa: Wydaw. Lekarskie PZWL, 1999. s.174-209.
28.
Hozyasz K.K.: Badanie stężenia homocysteiny oraz polimorfizmów genu reduktazy metylenotetrahydrofolianowej - nowy standard opieki nad chorymi na celiakię odmawiającymi leczenia dietetycznego? Pediat. Współcz. 2002; 4(3): 247-251.
29.
Ferguson S.E., Smith G.N., Walker M.C.: Maternal plasma homocysteine levels in women with preterm premature rupture of membranes. Med. Hypotheses 2001; 56(1): 85-90.
30.
Kim K.N., Kim Y.J., Chang N.: Effects of the interaction between the C677T 5,10- methylenetetrahydrofoIate reductase polymorphism and serum B vitamins on homocysteine levels in pregnant women. Eur. J. Clin. Nutr. 2004; 58(1): 10-16.
31.
Zachwieja K., Pietrzyk J.A., Dróżdż D., et al.: Hiperhomocysteinemia i jej związek z układem krzepnięcia w chorobach nerek u dzieci. Klin. Pediat. 2001; 9(1): 65-68.
32.
van. Guldener C., Robinson K.: Homocysteine and renal disease. Semin. Thromb. Hemost. 2000; 26(3): 313-324.
33.
Chan N.N.: Homocysteine and insulin levels in type 2 diabetic patients. Diabetes Care 2000; 23(7): 1041-1042.
34.
Boers G.H.: Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin. Thromb. Hemost. 2000; 26(3): 291-295.
35.
Malinow M.R., Nieto F.J., Kruger W.D., et al.: The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler. Thromb. Vasc. Biol. 1997; 17(6): 1157-1162.
36.
van Guldener C., Stehouwer C.D.: Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin. Thromb. Hemost. 2000; 26(3): 281-289.
37.
Brzezińska A., Balińska M.: Rola homocysteiny w procesie rozwoju zmian miażdżycowych na poziomie komórkowym. Post. Biol. Komórki 2000; 27(1): 81-96.
38.
Zhang X., Li H., Jin H., et al.: Effects of homocysteine on endothelial nitric oxide production. Am. J. Physiol. Renal Physiol. 2000; 279(4): F671-678.
39.
McQuillan B.M., Beilby J.P., Nidorf M., et al.: Hyperhomocysteinemia but not the C667T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. Circulation 1999; 99(18): 2383-2388.
41.
Collins J., Roberts R., Scott J.: Reports of independent analyses of data from the worldwide prospective collaborative study on immunotherapy for unexplained recurrent spontaneous abortion. Am. J. Reprod. Immunol. 1994; 32(4): 275-280.
42.
Regan L.: Endocrine factors in reccurent miscarriage. W: Recurrent miscarriage. Red. S. Daya (Infertility and Reproductive Medicine Clinics of North America 1996, Vol. 7, no. 4). s. 721-744.
43.
Hill J.A., Polgar K., Harlow B.L., et al.: Evidence of embryo- and trophoblast-toxic cellular immune response(s) in women with recurrent spontaneous abortion. Am. J. Obstet. Gynecol. 1992; 166(4): 1044-1052.
44.
McDonald S.D., Walker M.C.: Homocysteine levels in pregnant women who smoke cigarettes. Med. Hypotheses 2001; 57(6): 792-796.
45.
Mujumdar V.S., Tummalapalli C.M., Aru G.M., et al.: Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. Am. J. Physiol. Cell Physiol. 2002; 282(5): C 1009-1015.
46.
de Vries J.P., Dekker G.A., Huijgens P.C., et al.: Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br. J. Obstet. Gynaecol. 1997; 104(11): 1248- 125.
47.
Laivuori H., Kaaja R., Turpeinen U., et al.: Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet. Gynecol. 1999; 93(4): 489-493.
48.
Rajkovic A., Catalano P.M., Malinow M.R.: Elevated homocysteine levels with preeclampsia. Obstet. Gynecol. 1997; 90(2): 168-171.
49.
Pietrzyk J.J., Bik-Multanowski M., Sanak M., et al.: Mutacje 677C-T i 1298 A-C genu reduktazy metylenotetrahydrofolianowej jako czynnik ryzyka wystąpienia wad cewy nerwowej w populacji południowej Polski - wstępne wyniki badań. Pediat. Pol. 2000; 75(11): 863-868.
50.
van der Put N.M., Steegers-Theunissen R.P., Frosst P., et al.: Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346(8982): 1070-1071.
51.
McMullin M.F., Young P.B., Bailie K.E., et al.: Homocysteine and methylmalonic acid as indicators of folate and vitamin B12 deficiency in pregnancy. Clin. Lab. Haematol. 2001; 23(3): 161-165.
52.
Wilczyński J.R., Głowacka E., Tchórzewski H., et al: Rola wybranych cytokin w równowadze Th1/Th2 u ciężarnych z nadciśnieniem przemijającym w ciąży (NP). Ginekol. Po1. 2000; 71(6): 464-468.
53.
Kim K.N., Kim Y.J., Chang N.: Effects of the interaction between the C677T 5,10- methylenetetrahydrofoIate reductase polymorphism and serum B vitamins on homocysteine levels in pregnant women. Eur. J. Clin. Nutr. 2004; 58(1): 10-16.
54.
Hirsch S., Pia-De-la-Maza M., Yanez P., et al.: Hyperhomocysteinemia and endothelial function in young subjects: effects of vitamin supplementation. Clin. Cardiol. 2002; 25(11): 495-501.
55.
Jensen O.K., Rasmussen C. Mollerub F.: Hiperhomocysteinemia in rheumatoid arthritis: influence of methotrexate and folic acid supplementation. J. Rheumatol. 2002; 29(8): 1615-1618.
56.
Dimitrova K.R., DeGroot K., Myers A.K., et al.: Estrogen and homocysteine. Cardiovasc. Res. 2002; 53(3): 577-588.
57.
Hietala R., Turpeinen U., Laatikainen T.: Serum homocysteine at 16 weeks and subsequent preeclampsia. Obstet. Gynecol. 2001; 97(4): 527-529.
58.
van Wersch J.W., Janssens Y., Zandvoort J.A.: Folic acid, Vitamin B(12), and homocysteine in smoking and non-smoking pregnant women. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002; 103(1): 18-21.
59.
Khong T.Y.: Acute atherosis in pregnancies complicated by hypertension, smallfor- gestational-age infants, and diabetes mellitus. Arch. Pathol. Lab. Med. 1991; 115(7): 722-725.
60.
Pijnenborg R., Bland J.M., Robertson W.B., et al.: The pattern of interstitial trophoblastic invasion of the myometrium in early human pregnancy. Placenta 1981; 2(4): 303-316.
61.
Nadji P., Sommers S.C.: Lesions of toxemia in first trimester pregnancies. Am. J. Clin. Pathol. 1973; 59(3): 344-349.
62.
Khong T.Y., Pearce J.M., Robertson W.B.: Acute atherosis in preeclampsia: maternal determinants and fetal outcome in the presence of the lesion. Am. J. Obstet. Gynecol. 1987; 157(2): 360-363.
63.
Kitzmiller LL., Watt N., Driscoll S.G.: Decidual arteriopathy in hypertension and diabetes in pregnancy: immunofluorescent studies. Am. J. Obstet. Gynecol. 1981; 141(7): 773-779.
64.
Robertson W.B., Brosens I., Dixon H.G.: The pathological response of the vessels of the placental bed to hypertensive pregnancy. J. Pathol. Bacteriol. 1967; 93(2): 581- 592.
65.
Sheppard B.L., Bonnar J.: The ultrastructure of the arterial supply of the human placenta in pregnancy complicated by fetal growth retardation. Br. J. Obstet. Gynaecol. 1976; 83(12): 948-959.
66.
Wilson W.A., Gharevi A.E., Koike T., et al.: International consensus statement on preliminary classification criteria for definite anfiphospholipid syndrome. Arthritis. Rheum. 1999; 42(7): 1309-1311.
67.
Steegers-Theunissen R., Boers G.H., Blom H.J., et al.: Homocysteinemia and reccurent spontaneous abortion or abruptio placentae. Lancet 1992; 339(8801): 1122-1123.
68.
Clarke R. (oprac.): Obniżenie stężenia homocysteiny we krwi pod wpływem suplementacji, której podstawę stanowi kwas foliowy: metaanaliza randomizowanych badań. BMJ (Wyd. pol.) 1999; 3: 19-25.
69.
Słomko Z.: Niewydolność cieśniowoszyjkowa macicy. Klin. Perinatol. Ginekol. 1994; 10: 30-58.
70.
Jivraj S., Anstie B., Cheong Y.C., et al.: Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study. Hum. Reprod. 2001; 16(1): 102-106.
| eISSN: | 1734-025X |
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
